Recently, pharmaceutical giant Novo Nordisk (NVO), facing intensified market competition, has launched a series of significant initiatives. These include plans to substantially reduce the prices of its star GLP-1 drugs (such as Ozempic and Wegovy), while also announcing positive interim clinical data for its next-generation weight-loss drug. These developments have sparked extensive market discussion regarding its future growth prospects.
To address the increasingly fierce market competition, particularly in the rapidly growing weight-loss drug sector, Novo Nordisk has announced plans to significantly reduce the pricing of its popular GLP-1 drugs starting from 2027. At that time, the list price for these medications will be $675 per month, meaning patients could see price reductions of up to 50%. For example, Wegovy, currently used for weight loss, has a current list price of $1,349 per month. This price cut will make these treatments more accessible for patients with high-deductible insurance plans.
This pricing strategy comes at a time of continued pressure from the U.S. government to lower drug prices. Simultaneously, it could intensify competition with primary competitor Eli Lilly (LLY). Eli Lilly’s weight-loss drug, Zepbound, currently has a list price of approximately $1,100 per month, slightly lower than Wegovy, and has shown superior weight-loss efficacy in clinical trials compared to Wegovy. Novo Nordisk hopes that a more attractive price point will help it regain or consolidate market share and reduce reasons for existing patients to switch medications. Analysts believe that market share is crucial in the weight-loss market, where continuous medication is often necessary to prevent weight regain. The company plans to partially offset the revenue impact of the price cuts by reducing rebates.
Although price reduction news typically raises investor concerns about profit margins, some argue that this move could benefit Novo Nordisk’s stock in the long term. Currently, Novo Nordisk has a net profit margin of approximately 33%, giving it the capacity to exchange some profit for market share. While the price cuts seem significant, the actual impact might be less severe considering the reduction in rebates. The company’s stock is currently trading below 11 times its price-to-earnings ratio over the past 12 months. If this pricing strategy translates into stronger growth prospects, it could present an opportunity for shareholders.
Concurrently with the price cut announcement, Novo Nordisk is actively advancing its future product pipeline. On February 24th, the company released data from a Phase II study conducted in China for its investigational weight-loss drug, UBT251. The results showed that UBT251 helped participants achieve an average weight loss of up to 19.7% in just 24 weeks.
UBT251 is an investigational therapy that mimics the action of three different gut hormones (GLP-1, glucagon, and GIP), regulating blood sugar, insulin, and satiety through multiple pathways, potentially enhancing weight-loss effects. Novo Nordisk acquired the commercialization rights for this drug in most countries from a Chinese pharmaceutical company last year.
While cross-trial comparisons should be approached with caution, it’s worth noting that in a recent Phase III study conducted by Novo Nordisk comparing another investigational drug, CagriSema, with Zepbound, CagriSema achieved an average weight loss of 23% over 84 weeks, slightly below Zepbound’s 25.5%. In another 72-week study, Zepbound showed an average weight loss of 20.2%, only marginally better than UBT251’s performance over 24 weeks. This suggests that over a comparable study duration, UBT251’s weight-loss effect might be superior to both Zepbound and CagriSema.
Analysts point out that caution is warranted regarding UBT251’s potential. Firstly, the data from its study in China cannot directly support a U.S. marketing application. Secondly, the drug is still in the mid-stage research phase, and later-stage clinical trial results carry inherent uncertainties. More importantly, Eli Lilly is also developing its own triple agonist, retatrutide. Nevertheless, the positive progress of UBT251 offers new hope for Novo Nordisk.
